Gilead Sciences Inc. GILD, -1.15% announced Tuesday an agreement to purchase a 49.9% stake in private cancer treatment developer Tizona Therapeutics Inc. for $ 300 million. Gilead also received the option to purchase the rest of Tizona for up to an additional $ 1.25 billion, including possible future milestone payments. …
Read More »Gilead Sciences will pay $ 300 million for almost half of Tizona, has the option to buy the rest for $ 1.25 billion
